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A role for -actin in RNA
polymerase III transcription
Ping Hu,1 Si Wu,1 and Nouria Hernandez2,3
1Cold Spring Harbor Laboratory, Cold Spring Harbor,
New York 11724, USA; 2Howard Hughes Medical Institute,
Cold Spring Harbor Laboratory, Cold Spring Harbor,
New York 11724, USA
When transcription from the human U6 snRNA gene is
reconstituted with recombinant factors and purified
RNA polymerase III (pol III), pol III must be treated with
CK2 to be active. We show that highly purified pol III
contains associated -actin, and -actin localizes to an
active U6 promoter in vivo. Pol III immunoprecipitated
from IMR90 cells treated with a genotoxic agent lacks
associated -actin and is inactive in the reconstituted
assay. Transcription is regained upon treatment of pol III
with CK2 and addition of -actin. This suggests that
-actin associated with pol III is essential for basal pol
III transcription.
Supplemental material is available at http://www.genesdev.org.
Received August 27, 2004; revised version accepted October
8, 2004.
-actin has been extensively studied as a cytoplasmic
cytoskeletal protein that plays roles in intracellular traf-
ficking as well as in driving changes in cellular shape
associated with cell motility, cytokinesis, endocytosis,
and cell adhesion (for reviews, see Brakebusch and
Fassler 2003; Engqvist-Goldstein and Drubin 2003; Suet-
sugu and Takenawa 2003; Ascough 2004). However,
-actin is also a nuclear protein, and in this cellular com-
partment it is thought to play roles in the constitution of
the nucleoskeleton, in RNA processing and export, and
in transcription (for review, see Bettinger et al. 2004).
A role for actin in transcription is supported by two
general lines of evidence. First, a number of experiments
directly suggest an actin requirement for active tran-
scription. Thus, a factor stimulating pol II transcription
in vitro was found to copurify and probably correspond
to actin (Egly et al. 1984). Further, injection of anti-actin
antibodies into the nuclei of salamander oocytes results
in a contraction of the lateral loops of lampbrush chro-
mosomes similar to that observed upon injection of
transcription inhibitors, consistent with a role in tran-
scription (Scheer et al. 1984). Injection of a peptide acting
as a competitive inhibitor of a protein–protein con-
tact involving actin and the heterogenous nuclear RNP
(hnRNP) protein hrp36 into the salivary glands of Chi-
ronomus tentans disrupts global RNA polymerase (pol) II
transcription as measured by bromo-UTP incorporation,
an effect that is due at least in part to a decrease in
elongation as measured by run-on assays (Percipalle et al.
2003). Moreover, actin and nuclear myosin (NM1) asso-
ciate with RNA polymerase I, and NM1 can be localized
to active nucleolar transcription sites, an observation
that has prompted the suggestion that actin and NM1
may serve as a nucleolar motor involved in the transcrip-
tion of ribosomal RNA genes (Fomproix and Percipalle
2004). Second, at least some of the nuclear -actin is an
integral component of chromatin remodeling complexes
such as the BAF, BAP, and INO80 complexes, as well as
histone acetyl transferase complexes such as the Nu4A
and TIP60 complexes (for review, see Bettinger et al.
2004). In the SWI/SNF-like BAF complex, -actin stimu-
lates the ATPase activity of the Brg1 subunit and is re-
quired for association of the complex with the nuclear
matrix (Zhao et al. 1998). Moreover, it can, at least in
vitro, mediate actin filament binding of the complex in a
phosphatidylinositol 4,5-biphosphate (PIP2)-dependent
manner (Rando et al. 2002). In the INO80 complex, actin
may be required for efficient DNA binding, ATPase ac-
tivity, and nucleosome mobilization, as INO80 com-
plexes lacking actin as well as the actin-related proteins
Arp4 and Arp8 are deficient for these activities (Shen et
al. 2003).
We recently purified pol III from a human cell line
expressing a doubly tagged pol III subunit and observed
that a number of polypeptides, one of them -actin, co-
purify with the enzyme. We show here that -actin is
stably associated with pol III and is required for pol III
transcription in a reconstituted in vitro transcription
system. This suggests that -actin plays a direct role in
transcription, independent of any nuclear localization
function.
Results and Discussion
-actin is tightly associated with pol III
In earlier reports, we described the extensive purification
of a tagged pol III complex from a Hela cell line express-
ing Flag- and His-tagged HsRPC4 (HsRPC53) through
ammonium sulfate precipitation followed by anti-Flag
immunoaffinity chromatography, nickel affinity chro-
matography, and mini-Q chromatography, as summa-
rized in Figure 1A (Hu et al. 2002, 2003). In this purifi-
cation protocol, we observed copurification of pol III sub-
units with -actin (Hu et al. 2003), as shown in Figure 1B
for RPC1, the largest pol III subunit. Intriguingly, in this
purification, the U6 transcription activity profile across
the fractions closely followed the -actin profile. In par-
ticular, fraction 12, which contains less RPC1 but more
-actin than fraction 10, was more active for U6 tran-
scription than fraction 10 (see Fig. 4 in Hu et al. 2003),
consistent with a possible role of -actin in pol III tran-
scription. To determine whether -actin might also co-
purify with endogenous, untagged pol III, we partially
purified the endogenous enzyme according to a protocol
we developed previously (Sepehri Chong et al. 2001). At
the last step of this purification scheme, which as sum-
marized in Figure 1C corresponds to a sucrose gradient,
pol III formed a single peak and could reconstitute U6
transcription when supplemented with recombinant
TBP, Brf2, Bdp1, and SNAPc (Sepehri Chong et al. 2001).
[Keywords: RNA polymerase III; -actin; human U6 snRNA promoter;
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We examined the distribution of -actin across the su-
crose gradient fractions by immunoblot. We observed a
single peak of -actin, and as shown in Figure 1D, this
peak coincided with the peak of RPC1. Thus, upon pu-
rification of both tagged and endogenous pol III com-
plexes, we observe copurification of -actin, suggesting
that -actin is associated with pol III.
To examine how tightly -actin associates with pol III,
we performed nondenaturing immunoprecipitations
from HeLa cell extracts with an anti-RPC4 antibody.
The immunoprecipitates were then extensively washed
with buffers containing 600 mM KCl, 1M KCl, and 1.5M
KCl. As shown in Figure 1E, in all cases -actin was
specifically detected in the material immunoprecipi-
tated with the anti-RPC4, but not with preimmune, an-
tibody, although the signal was weaker in the sample
washed at the highest salt concentration (Fig. 1E, cf.
lanes 3 and 1). We could also detect -actin in immuno-
precipitates (washed with 600 mM KCl) performed with
anti-RPC1 and anti-RPC5, but not the corresponding
preimmune, antibodies, as shown in Figure 1F and G. In
contrast, the transcription factor Oct-1 was not detected
in these immunoprecipitates (data not shown).
To determine whether -actin can directly associate
with individual pol III subunits, we expressed 15 of the
17 pol III subunits as HA-tagged polypeptides by trans-
lation in vitro, as well as untagged -actin, and tested
them in coimmunoprecipitation experiments. Out of all
the pol III subunits except for RPABC1 (RPB5) and
RPABC5 (RPB10), which were not tested, we found that
-actin can associate directly with RPC3 (RPC62),
RPABC2 (RPB6), and RPABC3 (RPB8) (see Supplemen-
tary Table S1). Together, the results
described thus far suggest that -actin
is associated very tightly with the pol
III complex, probably through direct
protein–protein interactions with one
of more of the RPC3, RPABC2, and
RPABC3 subunits.
Both RPABC2 and RPABC3 are
common to all three RNA polymer-
ases (for review, see Schramm and
Hernandez 2002). Strikingly, in the
crystal structure of pol II, they are lo-
cated next to each other at the surface
of the enzyme (Cramer et al. 2001),
raising the possibility that they form
a patch, most likely in the three RNA
polymerases, for -actin attachment.
Indeed, actin has also been reported to
associate with pol I (Fomproix and
Percipalle 2004). RPC3 is unique to
pol III and so we cannot infer its lo-
cation in the pol III enzyme from the
pol II crystal structure. This subunit
is part of a subcomplex that also con-
tains two other subunits unique to
pol III, RPC6 (RPC39) and RPC7
(RPC32) (Wang and Roeder 1997), and
in the yeast enzyme, photochemical
cross-linking experiments performed
with a transcription initiation com-
plex indicated that it makes contact
with the DNA (Bartholomew et al.
1993). Perhaps this subunit resides
next to RPABC2 and RPABC3 in the
three-dimensional structure of pol III. Alternatively, it
may constitute a separate -actin anchor site on the pol
III enzyme.
-actin is located at promoter sequences of an actively
transcribed U6 gene in vivo
Given the tight association of -actin with pol III, we
tested whether -actin is associated with an actively
transcribed U6 gene in vivo by chromatin immunopre-
cipitation assays as described (Schramm et al. 2000;
Zhao et al. 2001; Hu et al. 2003). The chromatin immu-
noprecipitations were performed in actively growing
Hela and IMR90 cells, with similar results. As shown in
Figure 2, both the control primers (labeled C), which hy-
bridize to the promoter region of the transcriptionally
inactive U6-4 gene, and the test primers (labeled T),
which hybridize to the promoter region of the actively
transcribed U6-1 gene (Domitrovich and Kunkel 2003),
amplified the expected fragments from the starting chro-
matin material (Fig. 2, lanes 2,3), but not from material
mock-immunoprecipitated without antibody (Fig. 2,
lanes 4,5). When we performed the immunoprecipitation
with an antibody against the largest subunit of SNAPc
(SNAP190), which is required for U6 transcription, the
promoter region of the actively transcribed U6 gene, but
not that of the transcriptionally inactive U6 gene, was
amplified specifically, as expected (Fig. 2, lanes 6,7). In
contrast, with an antibody against TFIIB, which is not
required for U6 transcription, neither the promoter re-
gion of the active U6 gene nor that of the inactive U6
gene was amplified, as expected (Fig. 2, lanes 8,9). Thus,
Figure 1. -actin is associated with pol III. (A) Purification scheme of tagged pol III from a
HeLa cell line expressing Flag- and His-tagged RPC4. (B) -actin and RPC1 copurify during
mono Q chromatography. This panel is reprinted from Figure 4D in Hu et al. (2003) (© 2003
with permission from Elsevier) and shows immunoblots performed with anti-RPC1 and anti-
-actin antibodies. (C) Purification scheme of endogenous pol III. (D) -actin and pol III copu-
rify during sucrose gradient fractionation. The immunoblot was probed as in B. (E) The asso-
ciation of -actin with pol III is resistant to high salt. HeLa whole-cell extracts were incubated
with anti-RPC4 beads, the beads were then washed with 0.6, 1, or 1.5 M KCl as indicated
above the lanes, and the bound material was eluted, fractionated on a gel, and immunoblotted
with an anti--actin antibody. In lane 4, preimmune antibody beads were used. (F) HeLa
whole-cell extract was incubated with anti-RPC1 beads, the beads were washed with 0.6 M
KCl, and the bound material was analyzed as in E. (G) As in F except that the HeLa whole-cell
extract was incubated with anti-RPC5 beads.
-actin requirement in U6 transcription
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the chromatin immunoprecipitations are highly specific.
Very strikingly, with an antibody directed against -ac-
tin, the promoter region of the actively transcribed U6
gene was specifically amplified (Fig. 2, lanes 10,11).
Thus, in vivo, -actin is located close to the promoter
region of an actively transcribed U6 gene, consistent
with the possibility that it participates in the transcrip-
tion process.
-actin dissociates from pol III upon MMS treatment
To explore a possible role for -actin in pol III transcrip-
tion, we searched for conditions under which -actin
might be dissociated from the pol III complex, such that
we might compare the transcription activities of pol III
with or without -actin. Methane methylsulfonate
(MMS) treatment induces DNA damage and is known to
repress pol III transcription (Crighton et al. 2003). We
treated IMR90 cells with MMS and checked p53 levels
by immunoblot at various time points after treatment.
As shown in Figure 3A and quantitated (after normaliza-
tion to the TFIIB internal control signal) in Figure 3B,
p53 levels peaked 2 h after MMS treatment and then
diminished slowly over time, remaining detectable 5 h
after MMS treatment. This suggested that the cell re-
sponse to MMS peaks 2 h after treatment, and we there-
fore chose this time point to perform immunoprecipita-
tions with an anti-RPC4 antibody. The immunoprecipi-
tated material was then probed with an anti--actin
antibody.
As shown in Figure 3C, neither the RPC4 antibody
beads alone (Fig. 3C, lane 1) nor material precipitated
with pre-immune antibody beads (Fig. 3C, lanes 2,3) con-
tained detectable amounts of -actin. When the immu-
noprecipitations were performed with extracts from ac-
tively growing IMR90 cells, the RPC1 pol III subunit as
well -actin were coimmunoprecipitated with RPC4
(Fig. 3C, lane 4), consistent with the results above in
HeLa cells (Fig. 1E). However, with extracts from MMS-
treated IMR90 cells, no -actin was detected in the anti-
RPC4 immunoprecipitate, even though RPC1 was coim-
munoprecipitated as efficiently as in the actively grow-
ing IMR90 cells (Fig. 3C, cf. lanes 4 and 5). Yet, similar
levels of -actin (as well as RPC1) were present in the
starting extracts (Fig. 3C, lanes 6,7), indicating that MMS
treatment does not significantly change the total levels
of -actin. Together, these results suggest that after
DNA damage agent treatment, -actin is dissociated
from the pol III complex in IMR90 cells. Interestingly,
this effect was much less pronounced in HeLa cells,
where only a low proportion of the pol III-associated
-actin dissociated from the enzyme upon treatment
with MMS (data not shown).
The dissociation of -actin from pol III might be the
result of a global disruption or distortion of cytoskeletal
structures. We therefore examined the -tubulin and ac-
Figure 2. -actin can be localized to the promoter sequences of an
actively transcribed U6 gene. Cross-linked and sonicated chromatin
from actively growing Hela (top panel) or IMR90 (bottom panel)
cells was incubated with either no antibody (lanes 4,5), or antibodies
against the SNAP190 subunit of SNAPc (CS696, lanes 6,7), TFIIB
(CS396, lanes 8,9), or -actin (AC-74, Sigma, lanes 10,11). In each
case, the immunoprecipitated material was analyzed by PCR with
test primers (T) specific for the promoter of an actively transcribed
U6 gene, and control primers (C) specific for the promoter of an
inactive U6 gene. In lanes 2 and 3, the starting chromatin material
was directly analyzed by PCR. The order of the lanes in the bottom
panel, which are from the same gel, has been rearranged for clarity.
Figure 3. -actin dissociates from pol III upon MMS treatment in
IMR90 cells. (A) p53 peaks 2 h after MMS treatment. IMR90 cells
were treated with 1 mM MMS. Samples were analyzed by immu-
noblotting with anti-p53 and anti-TFIIB antibodies at the times in-
dicated after MMS treatment. (B) Quantitation of the p53 signals in
A after normalization to the TFIIB internal control. (C) -actin dis-
sociates from pol III after MMS treatment. Extracts from either ac-
tively growing (lanes 2,4) or MMS-treated (lanes 3,5) IMR90 cells
were incubated with preimmune (lanes 2,3) or anti-RPC4 (lanes 4,5)
antibody beads, the beads were washed with 0.6 M KCl, and the
bound material was eluted and analyzed by immunoblotting with
anti--actin and anti-RPC1 antibodies. In lane 1, the anti-RPC4
beads were not incubated with extract prior to immunoblotting
analysis of the bound material. Lanes 6 and 7 show immunoblots of
the starting material that was used for the immunoprecipitations.
(D) MMS treatment does not change the overall cytoskeleton struc-
ture. Actively growing (panels a–c,g–i) and MMS-treated (panels
d–f,j–l) IMR90 cells were stained with DAPI and either an immu-
nofluorescent-labeled anti--tubulin antibody or Alexa Fluor 568-
labeled phalloidin, which stains filamentous actin.
Hu et al.
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tin networks by immunofluorescence with an anti--tu-
bulin antibody and with phalloidin, which binds to fi-
brillar actin, with and without MMS treatment. Figure
3D shows examples of cells either left untreated or
treated with MMS. We could not detect any global
change in the overall tubulin or fibrillar actin networks
after MMS treatment (Fig. 3D, cf. panels a–c and d–f, and
panels g–i and j–l), suggesting that the dissociation of
-actin from pol III is not the result of an overall disrup-
tion of the cytoskeletal structure.
The U6 initiation complex is disrupted
after MMS treatment
We carried out chromatin immunoprecipitations with
quantitative PCR (qPCR) to monitor any changes on
U6-1 promoter occupancy prior to, and after, MMS treat-
ment. Figure 4A shows the ratios of the signals obtained
in material immunoprecipitated from either actively
growing or MMS-treated IMR90 cells to the signals ob-
tained in material immunoprecipitated from MMS-
treated cells. Thus, for MMS-treated cells, the ratio is
always 1. For RNA polymerase III, there was a twofold
decrease in the amount of protein associated with the
U6-1 promoter after MMS treatment. For TBP and Bdp1,
the reduction was larger, seven- and fourfold, respec-
tively. Strikingly, the levels of -actin associated with
the U6-1 promoter region decreased more than sevenfold
after MMS treatment. These results suggest that upon
MMS treatment, the U6 initiation complex as well as
-actin are largely dissociated from promoter sequences.
Notably, there is a much larger decrease in -actin asso-
ciation with the U6 promoter region compared to disso-
ciation of pol III, consistent with the idea that -actin
dissociates from pol III, but that only some of the pol III
dissociates from U6 sequences.
-actin is required for U6 transcription
We prepared whole-cell extracts from logarithmically
growing and MMS-treated IMR90 cells and tested their
abilities to support pol III transcription. As shown in
Figure 4B, extracts from untreated IMR90 cells sup-
ported robust transcription from both the type 3 U6 and
the type 2 VAI promoters (Fig. 4B, lane 1), whereas ex-
tracts from MMS-treated cells showed less activity, even
over a wide titration of extract (Fig. 4B, cf. lanes 2–5 and
1), consistent with the inhibition of tRNA transcription
in extracts from MMS-treated HeLa cells observed by
others (Crighton et al. 2003). To determine whether pol
III was active in extracts from MMS-treated cells, we
took advantage of a minimal U6 transcription system we
developed previously (Hu et al. 2003). We immunopre-
cipitated pol III from either untreated or MMS-treated
IMR90 cells with an anti-RPC4 antibody and checked
that equal amounts of enzyme were precipitated in both
cases by immunoblotting with an anti-RPC1 antibody,
as shown in Figure 4C. We then supplemented these pol
III complexes with recombinant TBP, Brf2, Bdp1, and
SNAPc, thus eliminating any potential MMS effect on
these proteins and allowing a direct comparison of the
activities of the enzymes. As shown in Figure 4D, pol III
immunoprecipitated from untreated IMR90 cells sup-
ported robust transcription in the minimal system (Fig.
4D, lane 1), whereas pol III from MMS-treated cells was
inactive (Fig. 4D, lanes 2,3). Pol III repression of type 2
tRNA promoters after MMS treatment results at least in
part from p53-mediated effects on TFIIIB; the TFIIIB as-
sociation with TFIIIC2 and pol III in solution is reduced,
as is the TFIIIB association with tRNA promoters in vivo
(Crighton et al. 2003). Our results suggest that at least in
certain cell types such as IMR90 cells, pol III transcrip-
tion repression results, in addition, from an inhibition of
the enzyme itself. Thus, MMS treatment apparently in-
activates several components of the RNA polymerase III
transcription machinery, and at least in the case of the
enzyme itself, the extent of this inactivation varies in
different cell types. Whether inactivation of RNA poly-
merase III is, like that of TFIIIB, dependent on p53, re-
mains to be determined.
We have shown before that CK2 phosphorylation of
the pol III complex is required for U6 transcription (Hu et
al. 2003). MMS treatment might result in dephosphory-
lation and thus inactivation of the pol III complex. How-
Figure 4. -actin is required for U6 transcription in vitro. (A) -ac-
tin dissociates from an active U6 promoter upon MMS treatment.
The Y-axis indicates the ratio of DNA amplified from actively grow-
ing IMR90 cells to DNA amplified from MMS-treated IMR90 cells.
The error bars are based on three independent PCR reactions with
the same templates and primers. (B) Extracts from MMS-treated
IMR90 cells show reduced pol III transcription. Extracts from ac-
tively growing (lane 1) and MMS-treated (lanes 2–5) IMR90 cells
were tested for transcription from the U6 and VAI promoters. (IC)
Internal control for RNA recovery. (C) Equal amounts of pol III were
precipitated from untreated and IMR90-treated cells. Pol III was
immunoprecipitated with an anti-RPC4 antibody, and the bound
material was analyzed by immunoblotting with anti-RPC1 antibod-
ies. (D) -actin is required for U6 transcription in a reconstituted
transcription system. SNAPc purified from baculovirus-infected in-
sect cells was treated with 60 µM LY294002 followed by 5 U of CK2
holoenzyme (SNAPc +I). TBP, Brf2, and Bdp1 were purified from E.
coli. These factors were supplemented with 6 µL of pol III immu-
noprecipitated from actively growing (lane 1) or 6 µL (lanes 2,4,6–9)
and 12 µL (lanes 3,5) of pol III immunoprecipitated from MMS-
treated IMR90 cells. In lanes 4, 5, 8, and 9, immunoprecipitated pol
III was incubated with 5 U of CK2 holoenzyme for 10 min at 30°C
followed by addition of 60 µM LY294002 (CK2). In lanes 6 and 7,
immunoprecipitated pol III was incubated first with LY294002 and
then with CK2. In lanes 6–9, increasing amounts (50 and 100 ng) of
-actin were added to the reactions. The various combinations of
factors were then tested for U6 transcription.
-actin requirement in U6 transcription
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ever, incubation of the pol III complex from MMS-
treated cells with CK2 followed by a CK2 inhibitor, thus
allowing phosphorylation (Fig. 4D, lanes labeled CK2;
see also Hu et al. 2003), did not restore transcription (Fig.
4D, lanes 4,5), suggesting that CK2 phosphorylation is
not the only requirement to activate pol III from MMS-
treated IMR90 cells.
Since upon MMS treatment we observed dissociation
of -actin from the pol III complex (Fig. 3C), we then
wondered whether pol III from MMS-treated cells might
be inactive because of the lack of -actin. We therefore
added to the minimal system recombinant, Escherichia
coli expressed -actin carrying an N-terminal Flag tag
and a C-terminal His tag, and tested the ability of pol III
from MMS-treated cells to support pol III transcription
when treated either first with a CK2 inhibitor and then
with CK2, thus preventing CK2 phosphorylation (Fig.
4D, lanes labeled +I), or first with CK2 and then with a
CK2 inhibitor, thus allowing phosphorylation. Strik-
ingly, in the presence of -actin, CK2-treated pol III from
MMS-treated cells was capable of supporting U6 tran-
scription in the minimal system (Fig. 4D, cf. lanes 8,9
and 4–7). Thus, inactive pol III purified from MMS-
treated IMR90 cells can be activated by a combination of
treatment with CK2 and addition of -actin. This result
has several implications. First, the target for CK2 phos-
phorylation within the pol III complex has not been de-
fined. Since a pol III complex devoid of -actin needs to
be phosphorylated by CK2 to regain activity, the CK2
target in the pol III complex is unlikely to be -actin.
Instead, it may correspond to one of the pol III subunits
or to one of the other tightly associated polypeptides
found in the preparation (see Hu et al. 2003). Second, the
requirement for addition of -actin suggests that -actin
itself is required for pol III transcription. Most of the
nuclear actin is thought to be in a form different from its
cytoplasmic filamentous form, perhaps in a monomeric
form (Bettinger et al. 2004). Moreover, since fusion of the
VP16 activation domain to the C terminus of actin pre-
vents polymerization (Posern et al. 2002), it is possible
that the recombinant actin we used to reconstitute tran-
scription, which carried small tags at both the N and C
termini, may not have been able to polymerize. Thus,
although this is an open question, it is conceivable that
the form of actin required for pol III transcription is mo-
nomeric actin.
Although several reports indicate that actin may be
required for transcription in vivo, there is, so far, little
evidence that it is required for the transcription process
itself rather than for proper localization or configuration
of transcription units. The observation that -actin is
required for pol III transcription in a purified system sug-
gests a direct role in basal transcription. What this role
consists of is presently not known, but it may not be
limited to just pol III transcription. Indeed, a number of
years ago, an activity that stimulated pol II transcription
in an in vitro transcription system was found to copurify
with actin, raising the possibility that actin is a pol II
transcription factor (Egly et al. 1984), and more recently,
actin was shown to be associated with pol I (Fomproix
and Percipalle 2004). It is conceivable, then, that actin is
required for transcription by all three RNA polymerases.
Materials and methods
The purification of pol III from untagged cells was performed as described
by Sepehri Chong et al. (2001).
The chromatin immunoprecipitations in Figure 2 were performed as
described by Schramm et al. (2000), Zhao et al. (2001), and Hu et al.
(2003). The promoter sequence of an actively transcribed U6 gene was
amplified with primers U6UP4 and U6L2, which amplify the U6-1 pro-
moter region. The control primers (U64-1 and U64-120) amplified the
promoter region of the U6-4 gene, which is transcriptionally inactive
(Domitrovich and Kunkel 2003). The chromatin immunoprecipitation in
Figure 4A was performed with the same primers as in Figure 2, but
quantitative PCR (qPCR) was used for amplification (Hu et al. 2004). The
double-stranded amplicons were labeled with SYBR, and the fluorescent
signals were detected with an ABI Prism 770 sequence-detection system
(Applied Biosystems). The qPCR conditions were one cycle with a 2-min
incubation at 50°C, followed by a 10-min incubation at 95°C, followed by
40 cycles with a 15-sec incubation at 95°C and 1-min incubation at 60°C.
For the images in Figure 3D, IMR90 cells were grown on coverslips
overnight at 37°C and then treated for 2 h with either 1 mM MMS in
DMSO or with DMSO alone. For the anti--tubulin staining, the cells
were then washed three times with prewarmed PBS, fixed with 2% para-
formaldehyde for 15 min at room temperature, washed three times with
PBS, and permeabilized with 0.5% Triton X-100 for 5 min at room tem-
perature. The cells were then washed three times with PBS, incubated
with 0.5% goat serum in PBS for 1 h, and with an anti--tubulin antibody
(1:1000, Sigma) for 1 h at room temperature. The cells were washed three
times with PBS followed by a 1-h incubation with Alexa Fluor 488-con-
jugated goat anti-mouse IgG (Molecular Probes) at a 1:1000 dilution in
0.5% goat serum. The slides were then washed four times with PBS. For
the actin stain, the cells were processed as above except that fixation was
with 3.7% formaldehyde for 10 min at room temperature, and the cells
were stained with Alexa Fluor 568-labeled phalloidin (1:40, Molecular
Probe) in the presence of 1% BSA at room temperature for 20 min. The
DNA was visualized by staining with 4, 6-diamidino-2-phenylindole
(DAPI) for 5 min at room temperature. The images were collected with a
Zeiss fluorescent microscope.
In Figure 4D, pol III was immunoprecipitated from either actively
growing or MMS-treated IMR90 cells with anti-RPC4 antibody beads.
The beads were washed three times with a buffer containing 400 mM
KCl and once with a buffer containing 100 mM KCl. The bound material
was eluted in Laemmli buffer and analyzed by immunoblotting with
anti-RPC1. The enzyme was complemented with 35 ng of TBP, 60 ng of
Brf2, 130 ng of Bdp1, 550 ng of SNAPc, and 50 and 100 ng of recombinant
-actin. Recombinant -actin was expressed in E. coli and carried an
N-terminal Flag tag and a C-terminal His tag.
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